Sprouting strategies and dead ends in anti-angiogenic targeting of NETs

Area of Science:

• Oncology
• Vascular Biology
• Drug Discovery

Background:

• Neuroendocrine tumors (NETs) are heterogeneous neoplasms known for high vascularization and proangiogenic factor production.
• Current therapies, including chemotherapy, show limited efficacy and significant toxicity due to poor selectivity.
• Developing targeted therapies is crucial for improving treatment outcomes in NET patients.

Purpose of the Study:

• To review mechanisms regulating vessel components in NET progression.
• To explore novel therapeutic targets beyond classical anti-angiogenic pathways.
• To propose combination therapies for enhanced NET treatment.

Main Methods:

• Review of existing literature on NET biology and angiogenesis.
• Analysis of classical anti-angiogenic therapies targeting the VEGF pathway.
• Exploration of emerging angiogenic targets including PDGFs, EGFs, FGFs, and semaphorins.

Main Results:

• NETs' complexity and heterogeneity pose challenges for conventional treatments.
• Classical anti-angiogenic therapies targeting VEGF have limitations.
• Emerging targets and combination strategies show potential for improved efficacy.

Conclusions:

• Targeting multiple components of vessel formation is essential for specific NET targeting.
• Combination therapies offer a promising approach to inhibit NET growth.
• Further research into novel angiogenic targets and combination strategies is warranted.